title: Methylglyoxal increases cardiomyocyte ischemia-reperfusion injury via glycative inhibition of thioredoxin activity.
abstract: Diabetes mellitus (DM) is closely related to cardiovascular morbidity and mortality, but the specific molecular basis linking DM with increased vulnerability to cardiovascular injury remains incompletely understood. Methylglyoxal (MG), a precursor to advanced glycation end products (AGEs), is increased in diabetic patient plasma, but its role in diabetic cardiovascular complications is unclear. Thioredoxin (Trx), a cytoprotective molecule with antiapoptotic function, has been demonstrated to be vulnerable to glycative inhibition, but whether Trx is glycatively inhibited by MG, thus contributing to increased cardiac injury, has never been investigated. Cultured H9c2 cardiomyocytes were treated with MG (200 muM) for 6 days. The following were determined pre- and post-simulated ischemia-reperfusion (SI-R; 8 h of hypoxia followed by 3 h of reoxygenation): cardiomyocyte death/apoptosis, Trx expression and activity, AGE formation, Trx-apoptosis-regulating kinase-1 (Trx-ASK1) complex formation, and p38 mitogen-activated protein kinase (MAPK) phosphorylation and activity. Compared with vehicle, MG significantly increased SI-R-induced cardiomyocyte LDH release and apoptosis (P < 0.01). Prior to SI-R, Trx activity was reduced in MG-treated cells, but Trx expression was increased moderately. Moreover, Trx-ASK1 complex formation was reduced, and both p38 MAPK activity and phosphorylation were increased. To investigate the effects of MG on Trx directly, recombinant human Trx (hTrx) was incubated with MG in vitro. Compared with vehicle, MG incubation markedly increased CML formation (a glycation footprint) and inhibited Trx activity. Finally, glycation inhibitor aminoguanidine administration during MG treatment of cultured cells reduced AGE formation, increased Trx activity, restored Trx-ASK1 interaction, and reduced p38 MAPK phosphorylation and activity, caspase-3 activation, and LDH release (P < 0.01). We demonstrated for the first time that methylglyoxal sensitized cultured cardiomyocytes to SI-R injury by posttranslational modification of Trx via glycation. Therapeutic interventions scavenging AGE precursors may attenuate ischemic-reperfusion injury in hyperglycemic state diseases such as diabetes.
authors.affiliation: Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA.
authors.forename: Xiao-Liang
authors.initials: XL
authors.lastname: Wang
authors.forename: Wayne B
authors.initials: WB
authors.lastname: Lau
authors.forename: Yue-Xing
authors.initials: YX
authors.lastname: Yuan
authors.forename: Ya-Jing
authors.initials: YJ
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Yi
authors.forename: Theodore A
authors.initials: TA
authors.lastname: Christopher
authors.forename: Bernard L
authors.initials: BL
authors.lastname: Lopez
authors.forename: Hui-Rong
authors.initials: HR
authors.lastname: Liu
authors.forename: Xin-Liang
authors.initials: XL
authors.lastname: Ma
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D002478:Cells, Cultured; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D007150:Immunohistochemistry; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D015428:Myocardial Reperfusion Injury / Q000473:pathology*; D032383:Myocytes, Cardiac / Q000473:pathology*; D011765:Pyruvaldehyde / Q000494:pharmacology*; D051381:Rats; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology; D013879:Thioredoxins / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
chemical_list: D017127:Glycation End Products, Advanced; D011994:Recombinant Proteins; C495697:Txn1 protein, rat; D013879:Thioredoxins; D011765:Pyruvaldehyde; D007770:L-Lactate Dehydrogenase; D048051:p38 Mitogen-Activated Protein Kinases
references.citation: Kidney Int. 2003 Mar;63(3):947-57
references.pmid: 12631075
references.citation: Methods Enzymol. 1995;252:199-208
references.pmid: 7476354
references.citation: J Cell Mol Med. 2009 Aug;13(8B):1751-1764
references.pmid: 19602045
references.citation: N Engl J Med. 1986 Feb 13;314(7):403-8
references.pmid: 3945267
references.citation: Diabetes. 2005 Nov;54(11):3274-81
references.pmid: 16249455
references.citation: Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11471-6
references.pmid: 15277664
references.citation: FASEB J. 2006 Jul;20(9):1555-7
references.pmid: 16723378
references.citation: Mol Cell Biochem. 1998 Apr;181(1-2):63-9
references.pmid: 9562242
references.citation: Electrophoresis. 2007 Nov;28(21):3940-7
references.pmid: 17924366
references.citation: Toxicology. 2010 Jan 31;268(1-2):89-97
references.pmid: 20004697
references.citation: Free Radic Biol Med. 2010 Aug 1;49(3):332-8
references.pmid: 20416371
references.citation: Diabetes Obes Metab. 2007 May;9(3):233-45
references.pmid: 17391149
references.citation: Nat Cell Biol. 2002 Oct;4(10):743-9
references.pmid: 12244325
references.citation: Diabetes. 1994 Jun;43(6):836-41
references.pmid: 8194672
references.citation: Free Radic Biol Med. 2000 Aug;29(3-4):312-22
references.pmid: 11035260
references.citation: Metabolism. 2006 Feb;55(2):232-6
references.pmid: 16423631
references.citation: Rejuvenation Res. 2006 Summer;9(2):274-8
references.pmid: 16706655
references.citation: FASEB J. 2006 Feb;20(2):259-68
references.pmid: 16449798
references.citation: EMBO J. 1998 May 1;17(9):2596-606
references.pmid: 9564042
references.citation: Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9745-9
references.pmid: 12119401
references.citation: J Clin Invest. 1994 Feb;93(2):759-67
references.pmid: 8113409
references.citation: Clin Biochem. 2005 Feb;38(2):103-15
references.pmid: 15642271
references.citation: J Cell Biochem. 2000 Mar;77(2):333-44
references.pmid: 10723098
references.citation: Mol Cell Biochem. 2007 Jul;301(1-2):251-7
references.pmid: 17549609
references.citation: Biochem Biophys Res Commun. 1999 Mar 5;256(1):89-93
references.pmid: 10066428
references.citation: Antioxid Redox Signal. 2004 Apr;6(2):405-12
references.pmid: 15025942
references.citation: Cardiovasc Res. 2002 Feb 1;53(2):414-22
references.pmid: 11827692
references.citation: Anticancer Res. 2003 May-Jun;23(3B):2425-33
references.pmid: 12894524
references.citation: Circ Res. 2002 Jun 28;90(12):1259-66
references.pmid: 12089063
references.citation: Antioxid Redox Signal. 2004 Feb;6(1):15-7
references.pmid: 14713332
references.citation: Life Sci. 2007 Feb 20;80(11):1051-6
references.pmid: 17174344
references.citation: Free Radic Biol Med. 2001 Jul 1;31(1):20-30
references.pmid: 11425486
references.citation: Free Radic Biol Med. 2000 Feb 1;28(3):418-27
references.pmid: 10699754
references.citation: Proc Natl Acad Sci U S A. 1998 May 12;95(10):5533-8
references.pmid: 9576917
references.citation: J Immunol Methods. 1983 Nov 25;64(3):313-20
references.pmid: 6199426
references.citation: Mol Cells. 2003 Apr 30;15(2):194-9
references.pmid: 12803482
references.citation: Curr Cardiol Rep. 2003 Sep;5(5):337
references.pmid: 12917044
references.citation: Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4630-4
references.pmid: 9539789
references.citation: Amino Acids. 2003 Dec;25(3-4):275-81
references.pmid: 14661090
references.citation: J Biol Chem. 2005 Apr 1;280(13):12310-5
references.pmid: 15677467
references.citation: Circulation. 2004 Aug 17;110(7):856-61
references.pmid: 15289372
references.citation: J Biol Chem. 1997 Jul 18;272(29):18453-9
references.pmid: 9218489
references.citation: J Biol Chem. 2004 Mar 5;279(10):8820-6
references.pmid: 14681238
references.citation: Antioxid Redox Signal. 2003 Oct;5(5):563-70
references.pmid: 14580311
references.citation: Ann N Y Acad Sci. 2005 Jun;1043:151-7
references.pmid: 16037234
references.citation: Am J Physiol Cell Physiol. 2008 Dec;295(6):C1510-7
references.pmid: 18842828
references.citation: J Pharmacol Toxicol Methods. 2005 Mar-Apr;51(2):153-7
references.pmid: 15767209